The pharma world is on tenterhooks, waiting to see how the Inflation Reduction Act will impact drug innovation and pricing, and how the Federal Trade Commission could foil M&A plans. As valid as these concerns are, however, they shouldn't overshadow what is arguably a more pressing issue: the shifting dynamics in the US payer landscape. The…
製薬業界は新らたな未知の領域に突入しています。米国市場の比類なき収益性や大規模なM&Aによる成長に依存するこれまでの製薬業界の発展を支える主要な前提が大きく揺らいでいます。 FDAの対応の変化、IRAの波及効果、商業的混乱、ディールメイキングの不確実性、研究開発におけるブレークスルーなど、製薬・バイオテク企業の展望を再構築するために重要となる5つの変化を特定しました。 Evaluateの「ワールドプレビュー2023」レポートは、2028年までの製薬業界の展望に関する詳細な分析や、業界が抱える疑問への答えを提供します。
As part of Evaluate’s partnership with Galen Growth, we are delighted to bring you this report on the emergence of artificial intelligence (AI) and the use of Generative…
The pharmaceutical sector is entering new and unfamiliar territory. Key assumptions, such as the unrivalled profitability of the US market and the reliance on large…
After a promising start to the year on the M&A front, things have slowed down significantly in the third quarter. While it was generally agreed that mega-mergers were…
After a promising start to the year on the M&A front, things have slowed down significantly in the third quarter. While it was generally agreed that mega-mergers were…
After a hopeful start in M&A for the year, did Q3 keep up the pace or change gears? Venture financing has seen a shift, and the IPO window appears to be nudging open.…
As part of Evaluate’s partnership with Galen Growth, we are delighted to bring you this report on the importance of clinical evidence within the digital healthcare…
After a hopeful start in M&A for the year, did Q3 keep up the pace or change gears? Venture financing has seen a shift, and the IPO window appears to be nudging open.…
As part of Evaluate’s partnership with Galen Growth, we are delighted to bring you this report on the importance of clinical evidence within the digital healthcare…
Step into Pharma’s Age of Uncertainty, where all is in flux. From the FDA's shifting mood and the ripple effects of the IRA to commercial upheavals, dealmaking…
